You are here: Industry Insights > Lynparza

News List

Lynparza Demonstrated Overall Survival Benefit for Prostate Cancer in Trial americanpharmaceuticalreview
April 26, 2020
AstraZeneca and Merck announced further positive results from the Phase III PROfound trial of Lynparza (olaparib) in men with metastatic castration-resistant prostate cancer (mCRPC) ...
Lynparza Granted Orphan Drug Designation in Japan for Pancreatic Cancer americanpharmaceuticalreview
March 23, 2020
AstraZeneca announced Lynparza (olaparib) has been granted orphan drug designation (ODD) in Japan for the maintenance treatment of germline BRCA-mutated (gBRCAm) curatively unresectable pancreatic cancer.
Cediranib trips up in Lynparza combo ovarian cancer trial pharmatimes
March 16, 2020
AstraZeneca and MSD have reported results from the Phase III GY004 trial, in which potential new medicine cediranib, when added to Lynparza (olaparib), did not meet the trial’s primary endpoint.
Lynparza regulatory submission granted Priority Review in the US for 1st-line maintenance treatment with bevacizumab in advanced ovarian cancer worldpharmanews
January 16, 2020
AstraZeneca and MSD Inc., Kenilworth, N.J., US (MSD: known as Merck & Co., Inc. inside the US and Canada) announced that a supplemental New Drug Application for Lynparza (olaparib) in combination with bevacizumab has been accepted and granted ...
FDA grants priority review for AstraZeneca’s Lynparza pharmaceutical-technology
January 15, 2020
The US Food and Drug Administration (FDA) has granted priority review for Lynparza (olaparib) in combination with bevacizumab to treat advanced ovarian cancer.
AZ, Merck's Lynparza lands FDA nod in pancreatic cancer fiercepharma
January 03, 2020
Earlier this month, FDA experts voted—barely—that the agency should approve AstraZeneca and Merck’s Lynparza in pancreatic cancer.
Lynparza approved by FDA to treat germline BRCA-mutated metastatic pancreatic cancer europeanpharmaceuticalreview
January 03, 2020
The FDA has approved Lynparza as a first-line treatment after it reduced the risk of disease progression or death by 47 percent in patients.
FDA advisory committee backs Lynparza use for pancreatic cancer pharmaceutical-technology
December 19, 2019
The US Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) has recommended the approval of AstraZeneca-Merck (MSD)’s Lynparza (olaparib) to treat ...
Is AZ, Merck's Lynparza approvable in pancreatic cancer? fiercepharma
December 17, 2019
When AstraZeneca and Merck & Co. unveiled in February that a study of Lynparza in pancreatic cancer had read out positively, there was much excitement in the oncology world.
AstraZeneca-Merck’s Lynparza approved in China for ovarian cancer pharmaceutical-technology
December 09, 2019
AstraZeneca and Merck (MSD) have received the National Medical Products Administration (NMPA) approval in China for Lynparza (olaparib) to treat ...

Previous page 1 2 3 4 5 6 7 Next page